Fetal MRI Acquisition and Sequence Development
Launched by MASSACHUSETTS GENERAL HOSPITAL · Feb 14, 2022
Trial Information
Current as of August 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Fetal MRI Acquisition and Sequence Development," is focused on improving the way we take images of unborn babies using a special type of scan called magnetic resonance imaging (MRI). The goal is to develop new techniques that will help create clearer images of the fetus, especially when there is movement. The researchers are also looking to enhance specific types of images that show different aspects of the baby's health and development.
To participate in this study, potential participants must meet certain criteria. Eligible candidates include pregnant women who do not have any conditions that would prevent them from undergoing an MRI, such as severe anxiety about small spaces (claustrophobia) or certain medical implants. Participants should also have a weight of less than 300 pounds, as this is the limit for the MRI equipment. Before anyone can join the trial, a quick interview will be conducted to ensure safety. For those who are accepted, they can expect to undergo an MRI scan to help improve the imaging techniques used for fetal health assessments. It’s important to note that this trial is not yet recruiting participants.
Gender
ALL
Eligibility criteria
- • Eligibility will be determined prior to the scan session by a pre-screening interview conducted either via telephone or in person asking about MR contraindications.
- Participants will be excluded from study entry or study completion when any of the following exclusion criteria are met at any time of screening or enrollment:
- • Claustrophobia sufficient to interfere with MRI or render the subject unable to complete an MRI scan
- • MRI contraindications (e.g., magnetically or mechanically activated implants)
- • Weight greater than or equal to 300lbs (weight limit of the MRI table)
- • Non-English speaking
- • Neurological conditions (i.e. epilepsy, multiple sclerosis, neurodegenerative diseases, memory disorders, brain tumor)
- • Past incidence of stroke or heart attack
- • Severe hypertension, blood disorders, advanced diabetes mellitus, or advanced cardiovascular disease
- • Hospitalization within 6 weeks prior to enrollment
- • Significant acute and/or chronic medical conditions, current use of medications that indicate the existence of significant medical conditions, and other unspecified reasons that make the subject unsuitable for enrollment at the discretion at the PI and a consulting MD.
- • Pregnant mothers with the following features will be excluded.
- • Mothers with contraindication to MRI (such as pacemaker, metal in body, exceeding scanner weight or bore diameter limits (550lbs, 70cm))
- • Mothers with claustrophobia
- • Mothers medically unstable for the MRI study
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials